Literature DB >> 10790000

Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial.

D J Cox1, R L Merkel, B Kovatchev, R Seward.   

Abstract

Driving performance of adult males with attention-deficit hyperactivity disorder (ADHD) was compared with matched controls in a double-blind (Ritalin vs. placebo) cross-over design, using a high-fidelity driving simulator. Seven ADHD and six non-ADHD drivers (mean age 22) were screened to rule out comorbidity and assess for ADHD, and then admitted to the General Clinical Research Center to control diet and sleep before testing. At 0800 and 1530, subjects consumed either a placebo or Ritalin pill in a counter-balanced manner, and at 0930 and 1700, subjects drove the simulator. After both drives, subjects rated their driving performance. Compared with non-ADHD subjects, ADHD subjects had more career driving accidents (p < .04) and motor vehicle violations (p = .059), drove worse on the simulator under placebo condition (p < .05), demonstrated significant improvement under the Ritalin condition (p < .05), rated themselves as driving poorer during the placebo condition (p = .05), and tended to perceive their driving to be better during the Ritalin condition (p = .07). This would suggest that individuals with ADHD should have the therapeutic benefit of a stimulant medication when operating a vehicle.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790000     DOI: 10.1097/00005053-200004000-00006

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  22 in total

1.  Treatment of attention-deficit hyperactivity disorder.

Authors:  Laurence Jerome
Journal:  CMAJ       Date:  2002-05-14       Impact factor: 8.262

2.  ADHD and driving safety.

Authors:  Laurence Jerome
Journal:  CMAJ       Date:  2003-07-08       Impact factor: 8.262

3.  Effects of treatment on the overall functioning of children with ADHD.

Authors:  Lily Hechtman
Journal:  Can Child Adolesc Psychiatr Rev       Date:  2005-08

4.  Adolescents with attention deficit and hyperactivity disorder/learning disability and their proneness to accidents.

Authors:  Uzi Brook; Mona Boaz
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 1.967

Review 5.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 6.  Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children?

Authors:  Josephine Elia; Victoria L Vetter
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

7.  Can Youth with Autism Spectrum Disorder Use Virtual Reality Driving Simulation Training to Evaluate and Improve Driving Performance? An Exploratory Study.

Authors:  Daniel J Cox; Timothy Brown; Veerle Ross; Matthew Moncrief; Rose Schmitt; Gary Gaffney; Ron Reeve
Journal:  J Autism Dev Disord       Date:  2017-08

8.  Driving on ice: impaired driving skills in current methamphetamine users.

Authors:  David Bosanquet; Hamish G Macdougall; Stephen J Rogers; Graham A Starmer; Rebecca McKetin; Alexander Blaszczynski; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2012-07-29       Impact factor: 4.530

9.  Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD).

Authors:  E Sobanski; D Sabljic; B Alm; G Skopp; N Kettler; R Mattern; P Strohbeck-Kühner
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

Review 10.  Do Pharmaceuticals Improve Driving in Individuals with ADHD? A Review of the Literature and Evidence for Clinical Practice.

Authors:  Craig B H Surman; Ronna Fried; Lauren Rhodewalt; Heidi Boland
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.